Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365983 | 0.85 | NPY5R (0.40) | NPY5RCYP17A1CYP1A2CYP21A2CYP2C19 | |
| SCHEMBL3364453 | 0.77 | CYP17A1 (0.32) | CYP17A1CYP1A2CYP21A2CYP2C19 | |
| SCHEMBL3367531 | 0.70 | SLC6A4 (0.30) | — | |
| SCHEMBL731895 | 0.70 | PARP1 (0.33) | PARP1 | |
| SCHEMBL3839594 | 0.69 | AVPR1A (0.60) | AVPR1ANPY5R | |
| SCHEMBL31394077 | 0.66 | AVPR1A (0.51) | AVPR1ANPY5RLRRK2OPRM1OPRD1 | |
| SCHEMBL4360871 | 0.66 | AVPR1A (0.54) | AVPR1ANPY5R | |
| SCHEMBL3841581 | 0.66 | AVPR1A (0.54) | AVPR1ANPY5R | |
| SCHEMBL31394738 | 0.66 | AVPR1A (0.47) | AVPR1ANPY5RLRRK2OPRM1OPRD1 | |
| SCHEMBL3842297 | 0.65 | AVPR1A (0.50) | AVPR1ANPY5ROPRM1OPRD1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324235-B2 | Heterocyclic spiro-compounds | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2134720-B1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2134720-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | Novartis Ag (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008119744-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | REN, NR3C2, CYP21A2 | AVPR1A 67/4885NPY5R 792/4885CYP17A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.